<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00533689</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-07-MG-209-CTIL</org_study_id>
    <nct_id>NCT00533689</nct_id>
  </id_info>
  <brief_title>Study of the Long-Term Effect of Frequent Anti-VEGF Dosing on Retinal Function in Patients With Neovascular AMD</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      THis study aims to determine whether frequent dosing of intravitreal injections of
      Ranibizumab (Lucentis) or Bevacizumab (Avastin), which act as VEGF inhibitors, has a
      deleterious effect on the retina, studied by electrophysiologic testing.

      This prospective, non-randomized clinical study will include patients assigned to
      intravitreal injection of Ranibizumab or Bevacizumab due to neovascular AMD. The patients
      will undergo repeat ophthalmic evaluation and intravitreal injections every 4-6 weeks, as
      long as will be deemed necessary. Periodic electrophysiologic evaluation including
      Electroretinogram (ERG), electro-oculogram (EOG) and Visual Evoked Potentials (VEP) tests
      will be performed every 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">January 2010</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">2008</enrollment>
  <condition>Electrophysiology</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electroretinography (ERG), Visual Evoked Potentials (VEP)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CNV secondary to AMD

          -  No other ocular disease

          -  No history of kerato-refractive surgery

          -  No epilepsy

          -  Ability to perform electrophysiologic study

        Exclusion Criteria:

          -  Pregnancy

          -  Minority

          -  Epilepsy

          -  History of kerato-refractive surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Michaella Goldstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anat Loewenstein, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ido Perlman, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michaella Goldstein, MD</last_name>
    <phone>+972-3-6925773</phone>
    <email>michgold@netvision.net.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shiri Soudry, MD</last_name>
    <phone>+972-3-6925773</phone>
    <email>shirizayit@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Departent of Ophthalmlogy, Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2007</study_first_posted>
  <last_update_submitted>September 20, 2007</last_update_submitted>
  <last_update_submitted_qc>September 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2007</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

